Literature DB >> 9083890

The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage.

Y Jin1, L Fuller, M Carreno, K Zucker, D Roth, V Esquenazi, T Karatzas, S J Swanson, A G Tzakis, J Miller.   

Abstract

Liver infiltrating lymphocytes (LIL) were isolated from HCV-positive (+) and HCV-negative (-) end-stage livers. Phenotypic analysis and functional studies using proliferative and lymphocytotoxic assays were performed with the isolated LIL. Two CD3+ lymphocyte populations were found in LIL using FITC anti-CD3 monoclonal antibodies (mAb). One was a bright fluorescence intensity population (as in PBL), and the other dim. We calculated the number of FITC-anti-CD3 mAbs bound per lymphocyte on PBL and LIL and found 80,040 +/- 4628 and 39,615 +/- 3932, respectively. Therefore, HCV+ and HCV- patient PBL contained approximately twice the number of CD3 molecules per cell than patient CD3+ LIL. LIL also contained approximately a threefold higher concentration of TCR alpha beta +, CD4-CD8-, and CD56,16 (NK) cells than the patient PBL. Thus, a major subset of LIL is phenotypically similar to mouse NK1.1+ "intermediate" T cells. LIL freshly isolated from HCV+ livers exhibited weak CTL activity against EBV- or Con A-transformed lymphoblast targets infected with vaccinia-HCV recombinant virus (rHCV) or primary hepatocyte cultured cells. However, after in vitro coculture of LIL with rHCV, these cells developed a strong cytotoxicity for the above targets. In contrast, LIL from HCV- livers were not cytotoxic against the same targets. Histochemical studies (in situ) demonstrated that these hepatocytes express CD95, and stains demonstrated apoptosis. The HCV+ hepatocytes also express class I MHC molecules and ICAM-1. The addition of mAb specific for these adhesion molecules inhibited CML activity. Short-term cultured hepatocytes (targets) from HCV+ and HCV- patients produced low levels of cytokines IL-1 beta, IL-2, IL-6, TNF alpha, and IFN-gamma but a high level of IL-8. It is speculated that LIL expressing reduced numbers of CD3 molecules may even function as immune regulators as proposed for intermediate T cells in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083890     DOI: 10.1023/a:1027326415164

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  24 in total

Review 1.  Mouse NK1.1+ T cells: a new family of T cells.

Authors:  A P Vicari; A Zlotnik
Journal:  Immunol Today       Date:  1996-02

2.  Transplant-associated autoimmune mechanisms in human hepatitis C virus infection.

Authors:  K Zucker; D Roth; R Cirocco; J Mathew; M Carreno; L Fuller; T Karatzas; Y Jin; G Burke; J Nery; M Webb; A Tzakis; V Esquenazi; J Miller
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

3.  Expression of the HTLV-III envelope gene by a recombinant vaccinia virus.

Authors:  S Chakrabarti; M Robert-Guroff; F Wong-Staal; R C Gallo; B Moss
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

4.  Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.

Authors:  M J Koziel; D Dudley; N Afdhal; Q L Choo; M Houghton; R Ralston; B D Walker
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Intrahepatic expression of hepatitis C virus antigens in chronic liver disease.

Authors:  K T Nouri-Aria; R Sallie; M Mizokami; B C Portmann; R Williams
Journal:  J Pathol       Date:  1995-01       Impact factor: 7.996

Review 6.  Does the immune response play a role in the pathogenesis of chronic liver disease?

Authors:  M U Mondelli; M Manns; C Ferrari
Journal:  Arch Pathol Lab Med       Date:  1988-05       Impact factor: 5.534

7.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.

Authors:  Y K Shimizu; M Hijikata; A Iwamoto; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity.

Authors:  E Rouvier; M F Luciani; P Golstein
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

Review 9.  NK1.1+ T cell receptor-alpha/beta+ cells: new clues to their origin, specificity, and function.

Authors:  H R MacDonald
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

10.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Authors:  P R Galle; W J Hofmann; H Walczak; H Schaller; G Otto; W Stremmel; P H Krammer; L Runkel
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  14 in total

1.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

Authors:  Michael L Washburn; Moses T Bility; Liguo Zhang; Grigoriy I Kovalev; Adam Buntzman; Jeffery A Frelinger; Walter Barry; Alexander Ploss; Charles M Rice; Lishan Su
Journal:  Gastroenterology       Date:  2011-01-13       Impact factor: 22.682

4.  Presence of active hepatitis associated with liver cirrhosis is a risk factor for mortality caused by posthepatectomy liver failure.

Authors:  H Eguchi; K Umeshita; M Sakon; H Nagano; Y Ito; S I Kishimoto; K Dono; S Nakamori; T Takeda; M Gotoh; K Wakasa; N Matsuura; M Monden
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

5.  Liver-directed gamma interferon gene delivery in chronic hepatitis C.

Authors:  Eui-Cheol Shin; Ulrike Protzer; Andreas Untergasser; Stephen M Feinstone; Charles M Rice; Dana Hasselschwert; Barbara Rehermann
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Expression of hepatitis C virus core protein in hepatocytes does not modulate proliferation or apoptosis of CD8+ T cells.

Authors:  Young-Hee Jin; I Nicholas Crispe; Sun Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

7.  Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.

Authors:  Burkhard J Manfras; Hans Weidenbach; Karl-Heinz Beckh; Peter Kern; Peter Möller; Guido Adler; Thomas Mertens; Bernhard O Boehm
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 8.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

9.  Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection.

Authors:  Michaela Lucas; Stephan Gadola; Ute Meier; Neil T Young; Gillian Harcourt; Anastasios Karadimitris; Nikki Coumi; Dave Brown; Geoff Dusheiko; Vincenzo Cerundolo; Paul Klenerman
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia.

Authors:  S Russi; G Lauletta; G Serviddio; S Sansonno; V Conteduca; L Sansonno; V De Re; D Sansonno
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.